Drug interactions, renal impairment and hypoglycaemia in a patient with Type II diabetes

British Journal of Clinical Pharmacology

Volumn 48, Issue 2, 1999, Pages 134-137

  Collin, M ^a   Mucklow, J C ^a  

^a UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENDROFLUMETHIAZIDE; COCODAMOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; METFORMIN; NAPROXEN; RAMIPRIL; RANITIDINE; SULFONYLUREA; TERAZOSIN;

ADULT; ARTICLE; BLADDER NECK STENOSIS; BLOOD VOLUME; CASE REPORT; DUODENUM ULCER; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PRIORITY JOURNAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; WATER-ELECTROLYTE BALANCE;

EID: 0032775442     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00996.x     Document Type: Article

References (13)

1. 1 Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990; 13: 696-704.
2. 2 Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin dependent diabetes mellitus. Drugs 1995; 49: 721-749.
3. 3 Ferner RE, Neil HAW. Sulphonylureas and hypoglycaemia. Br Med J 1988; 296: 949-950.
4. 4 Gerich JE. Oral hypoglycaemic agents. N Engl J Med 1989; 321; 1231-45.
5. 5 Skillman JM, Feldman J. The pharmacology of sulphonylureas. Am J Med 1981; 70: 361-372.
6. 6 Anonymous. Glibenclamide. In Therapeutic Drugs ed. Dollery CT. London: Churchill Livingstone 1991: G21-G26.
7. 7 Sturrock NDC, Struthers AD. Non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function. Br J Clin Pharmacol 1993; 35: 343-348.
8. 8 Levenson DJ, Simmons CE, Brenner BM. Arachidonic acid metabolism, prostaglandins and the kidney. Am J Med 1982; 72: 354-374.
9. 9 Gans RO, Hoorntje SJ, Donker AJ. Renal effects of angiotensin I converting enzyme inhibitors. Neth J Med 1988; 32: 247-264.
10. 10 Abdi A, Johns EJ. The effect of angiotensin II receptor antagonists on kidney function in two-kidney, two-clip Goldblatt hypertensive rats. Eur J Pharmacol 1997; 331: 185-192.
11. 11 Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P. Hypoglycaemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. Am J Med 1990; 89: 811-813.
12. 12 Herings RMC, de Boer A, Stricker BHCh, Leufkens HGM, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345: 1195-1198.
13. 13 Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.